Monday - August 4, 2025
European Commission Approves Subcutaneous RYBREVANT (amivantamab) for the Treatment of Patients With Advanced EGFR-mutated Non-Small Cell Lung Cancer
April 08, 2025
NEW BRUNSWICK, New Jersey, April 8 -- Janssen-Cilag International NV, a subsidiary of Johnson and Johnson, issued the following news release:

* * *

European Commission approves subcutaneous RYBREVANT (amivantamab) for the treatment of patients with advanced EGFR-mutated non-small cell lung cancer

Subcutaneous (SC) amivantamab offers patients greater convenience, reducing administration time from hours to minutes and with a five-fold reduction in infusion-re . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products